Chemotherapy rechallenge shows activity in late-line metastatic disease

◆ TRIAL DATA

A phase II trial found that patients with refractory metastatic colorectal cancer who had previously responded to a regimen for at least 4 months could benefit from rechallenge with the same chemotherapy, with or without targeted therapy, after a treatment-free interval. (Oncology Research)